Recent Posts

anonymous said:

Fast forward to July 4, 2025.
Entresto has a biosimiliar, so half the C.V. sales force is gone.
Lp(a) has taken a significant delay, and won't launch until middle 2027.
C.V. is left with an appallingly mismanaged Leqvio to keep the division afloat for two years.
Does Novartis eventually punt on C.V.?
Look at the pipeline, what is coming that inspires confidence?
Furthermore, they are too self-important to recognize it, but they clearly do not know what they are doing in the C.V. space, as they have destroyed their s.i.RNA and they are already off and running when it comes to destroying their ASO.
Entresto? O.K., but don't forget how they struggled with it in the beginning.
It probably won't happen, but it shouldn't come as a shock if they eventually move to three T.A.'s (maybe find a new home for renal) or find something to take the place of cardiovascular as a fourth pillar.

Click to expand...

anonymous said:

The storm is brewing!

Click to expand...

anonymous said:

All the decisions Bea and her leadership team has made has Peggy's fingerprints all over it. We all know who really is controlling the FMT.

Click to expand...

anonymous said:

Is Global Services AskGS?

Click to expand...